Drug-Induced Reactivation of Apoptosis Abrogates HIV-1 Infection

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Hanauske Abel, Hartmut M ^a,b   Saxena, Deepti ^b,j   Palumbo, Paul E ^b,j   Hanauske, Axel Rainer ^c,k   Luchessi, Augusto D ^a,l   Cambiaghi, Tavane D ^a,m   Hoque, Mainul ^a   Spino, Michael ^d,e   Gandolfi, Darlene D'Alliessi ^f   Heller, Debra S ^a   Singh, Sukhwinder ^a   Park, Myung Hee ^g   Cracchiolo, Bernadette M ^a   Tricta, Fernando ^e   Connelly, John ^e   Popowicz, Anthony M ^h   Cone, Richard A ⁱ   Holland, Bart ^a   Pe'ery, Tsafi ^a   Mathews, Michael B ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c Asklepios Clinic St George   (Germany)

^d UNIVERSITY OF TORONTO   (Canada)

^e ApoPharma Inc   (Canada)

^f MANHATTANVILLE COLLEGE   (United States)

^g NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^h ROCKEFELLER UNIVERSITY   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j DARTMOUTH MEDICAL SCHOOL   (United States)

^k ELI LILLY AND COMPANY   (United States)

^l UNIVERSITY OF CAMPINAS   (Brazil)

^m UNIVERSITY OF SÃO PAULO   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BATRAFEN VAGINALCREME; CASPASE 3; CICLOPIROX; DEFERIPRONE; INITIATION FACTOR 5A; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DNA DEGRADATION; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; GENITAL HERPES; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROXYLATION; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TOXICITY TESTING;

ANTI-HIV AGENTS; APOPTOSIS; CELLS, CULTURED; HIV INFECTIONS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84884503910     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074414     Document Type: Article

References (218)

1. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, et al. (2013) Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. PLoS Pathog 9: 1 - 12.
2. Everett H, McFadden G, (1999) Apoptosis: an innate immune response to virus infection. Trends Microbiol 7: 160-165.
3. Benedict CA, Norris PS, Ware CF, (2002) To kill or be killed: viral evasion of apoptosis. Nat Immunol 3: 1013-1018.
4. Lum JJ, Badley AD, (2003) Resistance to apoptosis: mechanism for the development of HIV reservoirs. Curr HIV Res 1: 261-274.
5. McLean JE, Ruck A, Shirazian A, Pooyaei-Mehr F, Zakeri ZF, (2008) Viral manipulation of cell death. Curr Pharm Des 14: 198-220.
6. Zhou Y, Zhang H, Siliciano JD, Siliciano RF, (2005) Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol 79: 2199-2210.
7. Swingler S, Mann AM, Zhou J, Swingler C, Stevenson M, (2007) Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein. PLoS Pathog 3: 1281-1290.
8. Fernandez Larrosa PN, Croci DO, Riva DA, Bibini M, Luzzi R, et al. (2008) Apoptosis resistance in HIV-1 persistently-infected cells is independent of active viral replication and involves modulation of the apoptotic mitochondrial pathway. Retrovirology 5: 19.
9. Venkatachari NJ, Buchanan WG, Ayyavoo V, (2008) Human immunodeficiency virus (HIV-1) infection selectively downregulates PD-1 expression in infected cells and protects the cells from early apoptosis in vitro and in vivo. Virology 376: 140-153.
10. Klase Z, Winograd R, Davis J, Carpio L, Hildreth R, et al. (2009) HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression. Retrovirology 6: 18.
11. Cosenza MA, Zhao ML, Lee SC, (2004) HIV-1 expression protects macrophages and microglia from apoptotic death. Neuropathol Appl Neurobiol 30: 478-490.
12. Giri MS, Nebozyhn M, Raymond A, Gekonge B, Hancock A, et al. (2009) Circulating Monocytes in HIV-1-Infected Viremic Subjects Exhibit an Antiapoptosis Gene Signature and Virus- and Host-Mediated Apoptosis Resistance. J Immunol 182: 4459-4470.
13. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, et al. (1995) Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1: 129-134.
14. Petrovas C, Mueller YM, Katsikis PD, (2005) Apoptosis of HIV-specific CD8+ T cells: an HIV evasion strategy. Cell Death Differ 12Suppl 1: 859-870.
15. Rethi B, Vivar N, Sammicheli S, Fluur C, Ruffin N, et al. (2008) Priming of T cells to Fas-mediated proliferative signals by interleukin-7. Blood 112: 1195-1204.
16. Gougeon ML, Olivier R, Garcia S, Guetard D, Dragic T, et al. (1991) [Demonstration of an engagement process towards cell death by apoptosis in lymphocytes of HIV infected patients]. C R Acad Sci III 312: 529-537.
17. Groux H, Monte D, Bourrez JM, Capron A, Ameisen JC, (1991) [Activation of CD4+ T-lymphocytes in asymptomatic HIV infected patients induce the program action of lymphocyte death by apoptosis]. C R Acad Sci III 312: 599-606.
18. Montagnier L, (2009) 25 years after HIV discovery: prospects for cure and vaccine (Nobel lecture). Angew Chem Int Ed Engl 48: 5815-5826.
19. Selliah N, Finkel TH, (2001) Biochemical mechanisms of HIV induced T cell apoptosis. Cell Death Differ 8: 127-136.
20. Debatin KM, Fulda S (2006) Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim; [Chichester]: Wiley-VCH. 2 v. p.
21. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, et al. (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683.
22. Andrus L, Szabo P, Grady RW, Hanauske AR, Huima-Byron T, et al. (1998) Antiretroviral effects of deoxyhypusyl hydroxylase inhibitors: a hypusine-dependent host cell mechanism for replication of human immunodeficiency virus type 1 (HIV-1). Biochem Pharmacol 55: 1807-1818.
23. Hoque M, Hanauske-Abel HM, Palumbo P, Saxena D, D'Alliessi Gandolfi D, et al. (2009) Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A. Retrovirology 6: 90.
24. Wermuth CG, (2006) Selective optimization of side activities: the SOSA approach. Drug Discov Today 11: 160-164.
25. Scott LE, Orvig C, (2009) Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. Chem Rev 109: 4885-4910.
26. Hanauske-Abel HM, Günzler V, (1982) A stereochemical concept for the catalytic mechanism of prolyl hydroxlyase. Applicability to classification and design of inhibitors. J Theor Biol 94: 421-455.
27. Majamaa K, Hanauske-Abel HM, Gunzler V, Kivirikko KI, (1984) The 2-oxoglutarate binding site of prolyl 4-hydroxylase. Identification of distinct subsites and evidence for 2-oxoglutarate decarboxylation in a ligand reaction at the enzyme-bound ferrous ion. Eur J Biochem 138: 239-245.
28. Majamaa K, Gunzler V, Hanauske-Abel HM, Myllyla R, Kivirikko KI, (1986) Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase. J Biol Chem 261: 7819-7823.
29. Hanauske-Abel HM, Popowicz AM, (2003) The HAG mechanism: a molecular rationale for the therapeutic application of iron chelators in human diseases involving the 2-oxoacid utilizing dioxygenases. Curr Med Chem 10: 1005-1019.
30. Costas M, Mehn MP, Jensen MP, Que L Jr, (2004) Dioxygen activation at mononuclear nonheme iron active sites: enzymes, models, and intermediates. Chem Rev 104: 939-986.
31. Hausinger RP, (2004) FeII/alpha-ketoglutarate-dependent hydroxylases and related enzymes. Crit Rev Biochem Mol Biol 39: 21-68.
32. Hoffart LM, Barr EW, Guyer RB, Bollinger JM Jr, Krebs C, (2006) Direct spectroscopic detection of a C-H-cleaving high-spin Fe(IV) complex in a prolyl-4-hydroxylase. Proc Natl Acad Sci U S A 103: 14738-14743.
33. Neidig ML, Brown CD, Kavana M, Choroba OW, Spencer JB, et al. (2006) Spectroscopic and electronic structure studies of the role of active site interactions in the decarboxylation reaction of alpha-keto acid-dependent dioxygenases. J Inorg Biochem 100: 2108-2116.
34. McCaffrey TA, Pomerantz KB, Sanborn TA, Spokojny AM, Du B, et al. (1995) Specific inhibition of eIF-5A and collagen hydroxylation by a single agent. Antiproliferative and fibrosuppressive effects on smooth muscle cells from human coronary arteries. J Clin Invest 95: 446-455.
35. Clement PM, Hanauske-Abel HM, Wolff EC, Kleinman HK, Park MH, (2002) The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. Int J Cancer 100: 491-498.
36. Hoffman BD, Hanauske-Abel HM, Flint A, Lalande M, (1991) A new class of reversible cell cycle inhibitors. Cytometry 12: 26-32.
37. Hanauske-Abel HM, Park MH, Hanauske AR, Popowicz AM, Lalande M, et al. (1994) Inhibition of the G1-S transition of the cell cycle by inhibitors of deoxyhypusine hydroxylation. Biochim Biophys Acta 1221: 115-124.
38. Hanauske-Abel HM, Slowinska B, Zagulska S, Wilson RC, Staiano-Coico L, et al. (1995) Detection of a sub-set of polysomal mRNAs associated with modulation of hypusine formation at the G1-S boundary. Proposal of a role for eIF-5A in onset of DNA replication. FEBS Lett 366: 92-98.
39. Vu VV, Emerson JP, Martinho M, Kim YS, Munck E, et al. (2009) Human deoxyhypusine hydroxylase, an enzyme involved in regulating cell growth, activates O2 with a nonheme diiron center. Proc Natl Acad Sci U S A 106: 14814-14819.
40. Abbruzzese A, Hanauske-Abel HM, Park MH, Henke S, Folk JE, (1991) The active site of deoxyhypusyl hydroxylase: use of catecholpeptides and their component chelator and peptide moieties as molecular probes. Biochim Biophys Acta 1077: 159-166.
41. Caraglia M, Marra M, Giuberti G, D'Alessandro AM, Baldi A, et al. (2003) The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells. J Biochem 133: 757-765.
42. Tome ME, Fiser SM, Payne CM, Gerner EW, (1997) Excess putrescine accumulation inhibits the formation of modified eukaryotic initiation factor 5A (eIF-5A) and induces apoptosis. Biochem J 328 (Pt 3): 847-854.
43. Reno F, Tontini A, Burattini S, Papa S, Falcieri E, et al. (1999) Mimosine induces apoptosis in the HL60 human tumor cell line. Apoptosis 4: 469-477.
44. Jasiulionis MG, Luchessi AD, Moreira AG, Souza PP, Suenaga AP, et al. (2007) Inhibition of eukaryotic translation initiation factor 5A (eIF5A) hypusination impairs melanoma growth. Cell Biochem Funct 25: 109-114.
45. Jin BF, He K, Wang HX, Wang J, Zhou T, et al. (2003) Proteomic analysis of ubiquitin-proteasome effects: insight into the function of eukaryotic initiation factor 5A. Oncogene 22: 4819-4830.
46. Lee SK, Lee J, Lee SI, Bae WJ, Lee YM, et al. (2009) N(1)-guanyl-1,7,-diamineoheptane, an inhibitor of deoxyhypusine synthase, suppresses differentiation and induces apoptosis via mitochondrial and AMPK pathways in immortalized and malignant human oral keratinocytes. J Oral Pathol Med 38: 792-800.
47. Taylor CA, Sun Z, Cliche DO, Ming H, Eshaque B, et al. (2007) Eukaryotic translation initiation factor 5A induces apoptosis in colon cancer cells and associates with the nucleus in response to tumour necrosis factor alpha signalling. Exp Cell Res 313: 437-449.
48. Sun Z, Cheng Z, Taylor CA, McConkey BJ, Thompson JE, (2010) Apoptosis induction by eIF5A1 involves activation of the intrinsic mitochondrial pathway. J Cell Physiol 223: 798-809.
49. Bevec D, Jaksche H, Oft M, Wohl T, Himmelspach M, et al. (1996) Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5A. Science 271: 1858-1860.
50. Ruhl M, Himmelspach M, Bahr GM, Hammerschmid F, Jaksche H, et al. (1993) Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans-activation. J Cell Biol 123: 1309-1320.
51. Bevec D, Klier H, Holter W, Tschachler E, Valent P, et al. (1994) Induced gene expression of the hypusine-containing protein eukaryotic initiation factor 5A in activated human T lymphocytes. Proc Natl Acad Sci U S A 91: 10829-10833.
52. Hauber I, Bevec D, Heukeshoven J, Kratzer F, Horn F, et al. (2005) Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy. J Clin Invest 115: 76-85.
53. Schafer B, Hauber I, Bunk A, Heukeshoven J, Dusedau A, et al. (2006) Inhibition of multidrug-resistant HIV-1 by interference with cellular S-adenosylmethionine decarboxylase activity. J Infect Dis 194: 740-750.
54. Hart R, Billaud JN, Choi SJ, Phillips TR, (2002) Effects of 1,8-Diaminooctane on the FIV Rev Regulatory System. Virology 304: 97-104.
55. Okada Y, Maeno E, (2001) Apoptosis, cell volume regulation and volume-regulatory chloride channels. Comp Biochem Physiol A Mol Integr Physiol 130: 377-383.
56. Maeno E, Ishizaki Y, Kanaseki T, Hazama A, Okada Y, (2000) Normotonic cell shrinkage because of disordered volume regulation is an early prerequisite to apoptosis. Proc Natl Acad Sci U S A 97: 9487-9492.
57. Nunez R, Sancho-Martinez SM, Novoa JM, Lopez-Hernandez FJ, (2010) Apoptotic volume decrease as a geometric determinant for cell dismantling into apoptotic bodies. Cell Death Differ 17: 1665-1671.
58. Barros LF, Hermosilla T, Castro J, (2001) Necrotic volume increase and the early physiology of necrosis. Comp Biochem Physiol A Mol Integr Physiol 130: 401-409.
59. Ly JD, Grubb DR, Lawen A, (2003) The mitochondrial membrane potential (Δψ(m)) in apoptosis; an update. Apoptosis 8: 115-128.
60. Soldani C, Scovassi AI, (2002) Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 7: 321-328.
61. Brunelle JK, Letai A, (2009) Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 122: 437-441.
62. Scheuring UJ, Sabzevari H, Corbeil J, Theofilopoulos AN, (1999) Differential expression profiles of apoptosis-affecting genes in HIV-infected cell lines and patient T cells. AIDS 13: 167-175.
63. Zauli G, Gibellini D, Caputo A, Bassini A, Negrini M, et al. (1995) The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. Blood 86: 3823-3834.
64. Zheng L, Yang Y, Guocai L, Pauza CD, Salvato MS, (2007) HIV Tat protein increases Bcl-2 expression in monocytes which inhibits monocyte apoptosis induced by tumor necrosis factor-alpha-related apoptosis-induced ligand. Intervirology 50: 224-228.
65. Wang Z, Morris GF, Reed JC, Kelly GD, Morris CB, (1999) Activation of Bcl-2 promoter-directed gene expression by the human immunodeficiency virus type-1 Tat protein. Virology 257: 502-510.
66. Moris A, Nobile C, Buseyne F, Porrot F, Abastado JP, et al. (2004) DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood 103: 2648-2654.
67. Sivakumaran H, van der Horst A, Fulcher AJ, Apolloni A, Lin MH, et al. (2009) Arginine methylation increases the stability of human immunodeficiency virus type 1 Tat. J Virol 83: 11694-11703.
68. Kubota S, Duan L, Furuta RA, Hatanaka M, Pomerantz RJ, (1996) Nuclear preservation and cytoplasmic degradation of human immunodeficiency virus type 1 Rev protein. J Virol 70: 1282-1287.
69. Cohen EA, Dehni G, Sodroski JG, Haseltine WA, (1990) Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol 64: 3097-3099.
70. Le Rouzic E, Morel M, Ayinde D, Belaidouni N, Letienne J, et al. (2008) Assembly with the Cul4A-DDB1DCAF1 ubiquitin ligase protects HIV-1 Vpr from proteasomal degradation. J Biol Chem 283: 21686-21692.
71. Conti L, Matarrese P, Varano B, Gauzzi MC, Sato A, et al. (2000) Dual role of the HIV-1 vpr protein in the modulation of the apoptotic response of T cells. J Immunol 165: 3293-3300.
72. Muthumani K, Hwang DS, Desai BM, Zhang D, Dayes N, et al. (2002) HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem 277: 37820-37831.
73. Arokium H, Kamata M, Chen I, (2009) Virion-associated Vpr of human immunodeficiency virus type 1 triggers activation of apoptotic events and enhances fas-induced apoptosis in human T cells. J Virol 83: 11283-11297.
74. Muthumani K, Zhang D, Hwang DS, Kudchodkar S, Dayes NS, et al. (2002) Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines. Oncogene 21: 4613-4625.
75. Jacotot E, Ferri KF, El Hamel C, Brenner C, Druillennec S, et al. (2001) Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J Exp Med 193: 509-519.
76. Snyder A, Alsauskas ZC, Leventhal JS, Rosenstiel PE, Gong P, et al. (2010) HIV-1 viral protein r induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cells. AIDS 24: 1107-1119.
77. Arunagiri C, Macreadie I, Hewish D, Azad A, (1997) A C-terminal domain of HIV-1 accessory protein Vpr is involved in penetration, mitochondrial dysfunction and apoptosis of human CD4+ lymphocytes. Apoptosis 2: 69-76.
78. Romani B, Engelbrecht S, (2009) Human immunodeficiency virus type 1 Vpr: functions and molecular interactions. J Gen Virol 90: 1795-1805.
79. Romani B, Engelbrecht S, Glashoff RH, (2010) Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J Gen Virol 91: 1-12.
80. Sanchez M, Galy B, Muckenthaler MU, Hentze MW, (2007) Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat Struct Mol Biol 14: 420-426.
81. Theil EC, (2007) Coordinating responses to iron and oxygen stress with DNA and mRNA promoters: the ferritin story. Biometals 20: 513-521.
82. New EJ, (2013) Tools to study distinct metal pools in biology. Dalton Trans 42: 3210-3219.
83. Llados i Vallory EA, Girot R, Lenoir G, Payet M, Houze P, et al. (1989) Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children. Eur J Pediatr 148: 503-506.
84. Glickstein H, El RB, Link G, Breuer W, Konijn AM, et al. (2006) Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. Blood 108: 3195-3203.
85. Glickstein H, El RB, Shvartsman M, Cabantchik ZI, (2005) Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 106: 3242-3250.
86. Fakih S, Podinovskaia M, Kong X, Schaible UE, Collins HL, et al. (2009) Monitoring intracellular labile iron pools: A novel fluorescent iron(III) sensor as a potential non-invasive diagnosis tool. J Pharm Sci 98: 2212-2226.
87. Lazdins JK, Alteri E, Klimkait T, Woods-Cook K, Walker MR, et al. (1991) Lack of effect of desferrioxamine on in-vitro HIV-1 replication. Lancet 338: 1341-1342.
88. Salhi Y, Costagliola D, Rebulla P, Dessi C, Karagiorga M, et al. (1998) Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients. J Acquir Immune Defic Syndr Hum Retrovirol 18: 473-478.
89. Hunt J, Richards RJ, Harwood R, Jacobs A, (1979) The effect of desferrioxamine on fibroblasts and collagen formation in cell cultures. Br J Haematol 41: 69-76.
90. Wang GL, Semenza GL, (1993) Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 82: 3610-3615.
91. Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, et al. (1993) High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259: 1749-1754.
92. Roberts L, Passmore JA, Williamson C, Little F, Bebell LM, et al. (2010) Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS 24: 819-831.
93. Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht FM, et al. (2006) Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses 22: 757-762.
94. Ullum H, Cozzi Lepri A, Bendtzen K, Victor J, Gotzsche PC, et al. (1997) Low production of interferon gamma is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. AIDS Res Hum Retroviruses 13: 1039-1046.
95. Orsilles MA, Pieri E, Cooke P, Caula C, (2006) IL-2 and IL-10 serum levels in HIV-1-infected patients with or without active antiretroviral therapy. APMIS 114: 55-60.
96. Stylianou E, Aukrust P, Kvale D, Muller F, Froland SS, (1999) IL-10 in HIV infection: increasing serum IL-10 levels with disease progression-down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol 116: 115-120.
97. Shive CL, Biancotto A, Funderburg NT, Pilch-Cooper HA, Valdez H, et al. (2012) HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease. J Acquir Immune Defic Syndr 61: 145-152.
98. Halicka HD, Bedner E, Darzynkiewicz Z, (2000) Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis. Exp Cell Res 260: 248-256.
99. Hasselmann DO, Rappl G, Tilgen W, Reinhold U, (2001) Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem 47: 1488-1489.
100. Smith MS, Brian EL, Pagano JS, (1987) Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine. J Virol 61: 3769-3773.
101. Schinazi RF, Lloyd RM Jr, Nguyen MH, Cannon DL, McMillan A, et al. (1993) Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 37: 875-881.
102. Mellors JW, Bazmi HZ, Schinazi RF, Roy BM, Hsiou Y, et al. (1995) Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother 39: 1087-1092.
103. Jonckheere H, Witvrouw M, De Clercq E, Anne J, (1998) Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1. AIDS Res Hum Retroviruses 14: 249-253.
104. Balzarini J, Perez-Perez MJ, Velazquez S, San-Felix A, Camarasa MJ, et al. (1995) Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives). Proc Natl Acad Sci U S A 92: 5470-5474.
105. Okamoto M, Makino M, Yamada K, Nakade K, Yuasa S, et al. (1996) Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells. Antiviral Res 31: 69-77.
106. Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, et al. (1993) Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 361: 650-654.
107. Balzarini J, De Clercq E, (2001) Rapid alternation of drug therapy is highly efficient in suppressing the emergence of mutant drug-resistant HIV strains in cell culture. AIDS Res Hum Retroviruses 17: 1625-1634.
108. Paintsil E, Grill SP, Dutschman GE, Cheng YC, (2009) Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture. AIDS Res Ther 6: 5.
109. Witvrouw M, Pannecouque C, Desmyter J, De Clercq E, Andries K, (2000) In vitro evaluation of the effect of temporary removal of HIV drug pressure. Antiviral Res 46: 215-221.
110. Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, et al. (1986) Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 327: 575-580.
111. Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, et al. (2006) Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis 6: 90.
112. Galen BT, Martin AP, Hazrati E, Garin A, Guzman E, et al. (2007) A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis 195: 1332-1339.
113. Wilson SS, Cheshenko N, Fakioglu E, Mesquita PM, Keller MJ, et al. (2009) Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. Antivir Ther 14: 1113-1124.
114. Gupta AK, (2001) Ciclopirox: an overview. Int J Dermatol 40: 305-310.
115. Kamada S, Kikkawa U, Tsujimoto Y, Hunter T, (2005) Nuclear translocation of caspase-3 is dependent on its proteolytic activation and recognition of a substrate-like protein(s). J Biol Chem 280: 857-860.
116. Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, et al. (2009) Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis 200: 599-608.
117. Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L, (1990) Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 48: 255-261.
118. Rider TH, Zook CE, Boettcher TL, Wick ST, Pancoast JS, et al. (2011) Broad-spectrum antiviral therapeutics. PLoS One 6: e22572.
119. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF, (1999) Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med 5: 29-33.
120. Hay S, Kannourakis G, (2002) A time to kill: viral manipulation of the cell death program. J Gen Virol 83: 1547-1564.
121. Malim MH, Emerman M, (2008) HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 3: 388-398.
122. Poon B, Chang MA, Chen IS, (2007) Vpr is required for efficient Nef expression from unintegrated human immunodeficiency virus type 1 DNA. J Virol 81: 10515-10523.
123. Wolf D, Witte V, Laffert B, Blume K, Stromer E, et al. (2001) HIV-1 Nef associated PAK and PI3-kinases stimulate Akt-independent Bad-phosphorylation to induce anti-apoptotic signals. Nat Med 7: 1217-1224.
124. Poon B, Chen IS, (2003) Human immunodeficiency virus type 1 (HIV-1) Vpr enhances expression from unintegrated HIV-1 DNA. J Virol 77: 3962-3972.
125. Casey L, Wen X, de Noronha CM, (2010) The functions of the HIV1 protein Vpr and its action through the DCAF1.DDB1.Cullin4 ubiquitin ligase. Cytokine 51: 1-9.
126. Bennasser Y, Bahraoui E, (2002) HIV-1 Tat protein induces interleukin-10 in human peripheral blood monocytes: involvement of protein kinase C-betaII and-delta. FASEB J 16: 546-554.
127. Schols D, De Clercq E, (1996) Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production. J Virol 70: 4953-4960.
128. Hirasawa K, Yoshida O, Fujinami T, Sohma K, Watanabe A, (2000) Adenine-induced selective apoptosis toward HIV chronically infected cells in vitro. Biochem Biophys Res Commun 273: 1025-1032.
129. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, et al. (1998) Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 281: 2027-2031.
130. Perez OD, Nolan GP, Magda D, Miller RA, Herzenberg LA, (2002) Motexafin gadolinium (Gd-Tex) selectively induces apoptosis in HIV-1 infected CD4+ T helper cells. Proc Natl Acad Sci U S A 99: 2270-2274.
131. Chen J, Ramos J, Sirisawad M, Miller R, Naumovski L, (2005) Motexafin gadolinium induces mitochondrially-mediated caspase-dependent apoptosis. Apoptosis 10: 1131-1142.
132. Hashemy SI, Ungerstedt JS, Zahedi Avval F, Holmgren A, (2006) Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 281: 10691-10697.
133. Masutani H, Ueda S, Yodoi J, (2005) The thioredoxin system in retroviral infection and apoptosis. Cell Death Differ 12Suppl 1: 991-998.
134. Jacquel A, Herrant M, Legros L, Belhacene N, Luciano F, et al. (2003) Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J 17: 2160-2162.
135. Decker RH, Dai Y, Grant S, (2001) The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ 8: 715-724.
136. Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, et al. (2008) Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 111: 3190-3199.
137. Berro R, de la Fuente C, Klase Z, Kehn K, Parvin L, et al. (2007) Identifying the membrane proteome of HIV-1 latently infected cells. J Biol Chem 282: 8207-8218.
138. Biglione S, Byers SA, Price JP, Nguyen VT, Bensaude O, et al. (2007) Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology 4: 47.
139. Fulda S, Galluzzi L, Kroemer G, (2010) Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9: 447-464.
140. Schrell UM, Rittig MG, Anders M, Kiesewetter F, Marschalek R, et al. (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg 86: 845-852.
141. Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, et al. (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86: 840-844.
142. Huyghe P, Dassonneville L, Fenaux P, Bailly C, (2004) Hydroxyurea-induced apoptosis in an EBV-immortalized lymphoblastoid cell line. Oncol Res 14: 235-245.
143. Amaru Calzada A, Pedrini O, Finazzi G, Leoni F, Mascagni P, et al. (2013) Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients. Exp Hematol 41: 253-260 e252.
144. Calzado MA, MacHo A, Lucena C, Munoz E, (2000) Hydroxyurea inhibits the transactivation of the HIV-long-terminal repeat (LTR) promoter. Clin Exp Immunol 120: 317-323.
145. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, et al. (1994) Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266: 801-805.
146. Garcia F, Plana M, Arnedo M, Ortiz GM, Miro JM, et al. (2003) A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS 17: 43-51.
147. Lafeuillade A, Hittinger G, Chadapaud S, Maillefet S, Rieu A, et al. (2002) The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations. HIV Clin Trials 3: 263-271.
148. Vila J, Nugier F, Bargues G, Vallet T, Peyramond D, et al. (1997) Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 350: 635-636.
149. Malley SD, Grange JM, Hamedi-Sangsari F, Vila JR, (1994) Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci U S A 91: 11017-11021.
150. Park MH, Cooper HL, Folk JE, (1982) The biosynthesis of protein-bound hypusine (N epsilon-(4-amino-2-hydroxybutyl)lysine). Lysine as the amino acid precursor and the intermediate role of deoxyhypusine (N epsilon-(4-aminobutyl)lysine). J Biol Chem 257: 7217-7222.
151. Park MH, Wolff EC, Folk JE, (1993) Hypusine: its post-translational formation in eukaryotic initiation factor 5A and its potential role in cellular regulation. Biofactors 4: 95-104.
152. Li Q, Smith AJ, Schacker TW, Carlis JV, Duan L, et al. (2009) Microarray Analysis of Lymphatic Tissue Reveals Stage-Specific, Gene Expression Signatures in HIV-1 Infection. J Immunol 183: 1975-1982.
153. Tschank G, Brocks DG, Engelbart K, Mohr J, Baader E, et al. (1991) Inhibition of prolyl hydroxylation and procollagen processing in chick-embryo calvaria by a derivative of pyridine-2,4-dicarboxylate. Characterization of the diethyl ester as a proinhibitor. Biochem J 275 (Pt 2): 469-476.
154. Cracchiolo BM, Heller DS, Clement PM, Wolff EC, Park MH, et al. (2004) Eukaryotic initiation factor 5A-1 (eIF5A-1) as a diagnostic marker for aberrant proliferation in intraepithelial neoplasia of the vulva. Gynecol Oncol 94: 217-222.
155. Zhou H, Shen T, Luo Y, Liu L, Chen W, et al. (2010) The antitumor activity of the fungicide ciclopirox. Int J Cancer 127: 2467-2477.
156. Nekhai S, Kumari N, Dhawan S, (2013) Role of cellular iron and oxygen in the regulation of HIV-1 infection. Future Virol 8: 301-311.
157. van Asbeck BS, Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS, et al. (2001) Anti-HIV effect of iron chelators: different mechanisms involved. J Clin Virol 20: 141-147.
158. Breuer D, Kotelkin A, Ammosova T, Kumari N, Ivanov A, et al. (2012) CDK2 regulates HIV-1 transcription by phosphorylation of CDK9 on serine 90. Retrovirology 9: 94.
159. Debebe Z, Ammosova T, Breuer D, Lovejoy DB, Kalinowski DS, et al. (2011) Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol 79: 185-196.
160. Debebe Z, Ammosova T, Jerebtsova M, Kurantsin-Mills J, Niu X, et al. (2007) Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology 367: 324-333.
161. Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ, et al. (2000) Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. J Infect Dis 181: 484-490.
162. Georgiou NA, van der Bruggen T, Oudshoorn M, Hider RC, Marx JJ, et al. (2002) Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis. Eur J Clin Invest 32Suppl 1: 91-96.
163. Traore HN, Meyer D, (2004) The effect of iron overload on in vitro HIV-1 infection. J Clin Virol 31Suppl 1: S92-98.
164. Richardson DR, (2005) Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr Med Chem 12: 2711-2729.
165. Günzler V, Majamaa K, Hanauske-Abel HM, Kivirikko KI, (1986) Catalytically active ferrous ions are not released from prolyl 4-hydroxylase under turnover conditions. Biochim Biophys Acta 873: 36-44.
166. Linden T, Katschinski DM, Eckhardt K, Scheid A, Pagel H, et al. (2003) The antimycotic ciclopirox olamine induces HIF-1alpha stability, VEGF expression, and angiogenesis. FASEB J 17: 761-763.
167. Hanauske-Abel HM (1996) Fibrosis: Representative molecular elements, a basic concept, and emerging targets for suppressive treatment. In: Zakim D, Boyer TD, editors. Hepatology A Textbook of Liver Disease. Philadelphia: W.B. Saunders. pp. 465-506.
168. Zeng M, Southern PJ, Reilly CS, Beilman GJ, Chipman JG, et al. (2012) Lymphoid tissue damage in HIV-1 infection depletes naive T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog 8: e1002437.
169. Schacker TW, Reilly C, Beilman GJ, Taylor J, Skarda D, et al. (2005) Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count. AIDS 19: 2169-2171.
170. Saletta F, Suryo Rahmanto Y, Noulsri E, Richardson DR, (2010) Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53. Mol Pharmacol 77: 443-458.
171. Deshmane SL, Mukerjee R, Fan S, Del Valle L, Michiels C, et al. (2009) Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1alpha expression. J Biol Chem 284: 11364-11373.
172. Chaston TB, Richardson DR, (2003) Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol 73: 200-210.
173. Lukmantara AY, Kalinowski DS, Kumar N, Richardson DR, (2013) Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy. Bioorg Med Chem Lett 23: 967-974.
174. Steinhauser S, Heinz U, Bartholomä M, Weyhermüller T, Nick H, et al. (2004) Complex formation of ICL670 and related ligands with FeIII and FeII. Eur J Inorg Chem: 4177-4192.
175. Gao J, Richardson DR, (2001) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood 98: 842-850.
176. Cano VS, Medrano FJ, Park MH, Valentini SR, (2010) Evidence for conformational changes in the yeast deoxyhypusine hydroxylase Lia1 upon iron displacement from its active site. Amino Acids 38: 479-490.
177. Zhao LJ, Jian H, Zhu H, (2004) HIV-1 auxiliary regulatory protein Vpr promotes ubiquitination and turnover of Vpr mutants containing the L64P mutation. FEBS Lett 563: 170-178.
178. Kogan M, Rappaport J, (2011) HIV-1 Accessory Protein Vpr: Relevance in the Pathogenesis of HIV and Potential for Therapeutic Intervention. Retrovirology 8: 25.
179. Wang J, Shackelford JM, Selliah N, Shivers DK, O'Neill E, et al. (2008) The HIV-1 Vif protein mediates degradation of Vpr and reduces Vpr-induced cell cycle arrest. DNA Cell Biol 27: 267-277.
180. Nonaka M, Hashimoto Y, Takeshima SN, Aida Y, (2009) The human immunodeficiency virus type 1 Vpr protein and its carboxy-terminally truncated form induce apoptosis in tumor cells. Cancer Cell Int 9: 20.
181. Muthumani K, Lambert VM, Sardesai NY, Kim JJ, Heller R, et al. (2009) Analysis of the potential for HIV-1 Vpr as an anti-cancer agent. Curr HIV Res 7: 144-152.
182. Brockman MA, Kwon DS, Tighe DP, Pavlik DF, Rosato PC, et al. (2009) IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood 114: 346-356.
183. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, et al. (2009) Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 83: 3719-3733.
184. Blackburn SD, Wherry EJ, (2007) IL-10, T cell exhaustion and viral persistence. Trends Microbiol 15: 143-146.
185. Gee K, Angel JB, Ma W, Mishra S, Gajanayaka N, et al. (2006) Intracellular HIV-Tat expression induces IL-10 synthesis by the CREB-1 transcription factor through Ser133 phosphorylation and its regulation by the ERK1/2 MAPK in human monocytic cells. J Biol Chem 281: 31647-31658.
186. Cohen SB, Crawley JB, Kahan MC, Feldmann M, Foxwell BM, (1997) Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology 92: 1-5.
187. Sozzani S, Ghezzi S, Iannolo G, Luini W, Borsatti A, et al. (1998) Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J Exp Med 187: 439-444.
188. Neumann AU, Tubiana R, Calvez V, Robert C, Li TS, et al. (1999) HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS 13: 677-683.
189. Harrigan PR, Whaley M, Montaner JS, (1999) Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 13: F59-62.
190. Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, et al. (2010) Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 24: 2803-2808.
191. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9: 727-728.
192. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, et al. (2009) Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 106: 9403-9408.
193. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, et al. (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5: 512-517.
194. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, et al. (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360: 692-698.
195. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, et al. (2011) Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 117: 2791-2799.
196. Hinkula J, Walther-Jallow L, Lauren A, Makitalo B, Oberg M, et al. (2009) Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells. Vaccine 27: 6424-6431.
197. Spetz AL, Sorensen AS, Walther-Jallow L, Wahren B, Andersson J, et al. (2002) Induction of HIV-1-specific immunity after vaccination with apoptotic HIV-1/murine leukemia virus-infected cells. J Immunol 169: 5771-5779.
198. Johansson U, Walther-Jallow L, Smed-Sorensen A, Spetz AL, (2007) Triggering of dendritic cell responses after exposure to activated, but not resting, apoptotic PBMCs. J Immunol 179: 1711-1720.
199. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, et al. (2000) Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 108: 305-312.
200. Jones K (2011) Children with thalassemia at risk for HIV. Med India. Available at http://wwwmedindianet/news/Children-With-Thalassemia-at-Risk-for-HIV-79142-1htm.
201. Bhavsar H, Patel K, Vegad M, Madan M, Pandey A, et al. (2011) Prevalence of HIV, Hepatitis B and Hepatitis C infection in Thalassemia major patients in tertiary care hospital, Gujarat. Nat J Integr Res Med 2: 47-50.
202. Mathur M, Wanjari K, Turbadkar D (2008) Seroprevalence of HIV, hepatitis C and hepatitis B in multitransfused thalassemics. Ind J Med Microbiol: 205-206.
203. Sen S, Mishra NM, Giri T, Pande I, Khare SD, et al. (1993) Acquired immunodeficiency syndrome (AIDS) in multitransfused children with thalassemia. Indian Pediatr 30: 455-460.
204. al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, et al. (1995) Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol 91: 224-229.
205. Spinillo A, Zara F, Gardella B, Preti E, Mainini R, et al. (2005) The effect of vaginal candidiasis on the shedding of human immunodeficiency virus in cervicovaginal secretions. Am J Obstet Gynecol 192: 774-779.
206. Niewerth M, Kunze D, Seibold M, Schaller M, Korting HC, et al. (2003) Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother 47: 1805-1817.
207. Nenoff P, Taneva E, Pfeil B, Oswald U, Haustein UF, (1999) In vitro activity of rilopirox against fluconazole-susceptible and fluconazole-resistant Candida isolates from patients with HIV infection. Mycoses 42: 55-60.
208. Song S, Christova T, Perusini S, Alizadeh S, Bao RY, et al. (2011) Wnt inhibitor screen reveals iron dependence of beta-catenin signaling in cancers. Cancer Res 71: 7628-7639.
209. Minden MD, Hogge DE, Weir SJ, Kasper J, Patton L, et al. (2012) Clinical Proof of Concept Trial of Oral Ciclopirox Olamine in Patients with Relapsed/ Refractory Hematologic Malignancy. 54th ASH Annual Meeting. Atlanta, GA, Dec. 8-11, 2012; #1372. See https://ash.confex.com/ash/2012/webprogram/Paper46498.html.
210. Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, et al. (2009) Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 114: 3064-3073.
211. Zhu Y, Roshal M, Li F, Blackett J, Planelles V, (2003) Upregulation of survivin by HIV-1 Vpr. Apoptosis 8: 71-79.
212. Wainberg Z, Oliveira M, Lerner S, Tao Y, Brenner BG, (1997) Modulation of stress protein (hsp27 and hsp70) expression in CD4+ lymphocytic cells following acute infection with human immunodeficiency virus type-1. Virology 233: 364-373.
213. Abramovitch RA, Knaus EE, (1975) The direct thionation and aminoalkylation of pyridine 1-oxides and related reaction. J Heterocycl Chem 12: 683-690.
214. ACTG Laboratory Technologist Committee (2004) Preparation of PHA-stimulated uninfected donor peripheral blood mononuclear cells. Available at https://www.hanc.info/labs/labresources/procedures/ACTGIMPAACT%20Lab%20Manual/Preparation%20of%20PHA-Stimulated%20Uninfected%20Donor%20PBMCs.pdf.
215. Chen BK, Saksela K, Andino R, Baltimore D, (1994) Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J Virol 68: 654-660.
216. Pearse G, (2006) Histopathology of the thymus. Toxicol Pathol 34: 515-547.
217. Carambula SF, Matikainen T, Lynch MP, Flavell RA, Goncalves PB, et al. (2002) Caspase-3 is a pivotal mediator of apoptosis during regression of the ovarian corpus luteum. Endocrinology 143: 1495-1501.
218. Raymond KN, Cattano CJ, (1979) Coordination chemistry ans microbial iron transport. Acc Chem Res 12: 183-227.